Stockreport

Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals [Yahoo! Finance]

Annexon, Inc. - common stock  (ANNX) 
PDF candidate, ANX005, a monoclonal antibody, in patients with Guillain-Barré syndrome (GBS). Per the data readout from the pivotal phase III study, treatment with a singl [Read more]